<DOC>
	<DOCNO>NCT00285103</DOCNO>
	<brief_summary>The purpose study determine whether SPC2996 effective safe treatment Chronic Lymphocytic Leukaemia ( CLL )</brief_summary>
	<brief_title>SPC2996 Chronic Lymphocytic Leukaemia</brief_title>
	<detailed_description>Chronic Lymphocytic Leukaemia ( CLL ) common leukaemia adult US Western Europe . Many patient suffer CLL tumour cell express high amount Bcl-2 protein . Since expression Bcl-2 inhibits apoptosis , possible gene participates pathogenesis CLL . By lower Bcl-2 protein tumour cell cell may go apoptosis due change balance pro- anti apoptotic protein thereby might possible induce tumour response . The study open-labelled , international , multicenter , dose escalate phase I/II study patient receive 6 , 3 , 2 1 dose ( ) SPC2996 , LNA antisense molecule Bcl-2 , period 2 week , follow 6 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>patient relapse refractory Chronic Lymphocytic Leukaemia require therapy screen blood sample must show circulate lymphocyte count 5 x 109/L circulate lymphocyte express phenotype CD5+CD20+CD23+ . The PCR Bcl2 mRNA level must positive patient must 18 year old give informed consent . previous treatment rituximab , alemtuzumab autologous stem cell transplantation within 6 month prior Visit 1 allogeneic stem cell transplantation time patient receive anticancer therapy , glucocorticoid radiotherapy within 4 week prior Visit 1 patient know suspected transformation CLL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Antisense , mRNA antagonist , Bcl-2 , CLL</keyword>
</DOC>